Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1990 Jun 1;171(6):2025–2041. doi: 10.1084/jem.171.6.2025

Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium

PMCID: PMC2187940  PMID: 1972179

Abstract

Eosinophils (EOs) participate in a variety of inflammatory states characterized by endothelial cell damage, such as vasculitis, pneumonitis, and endocarditis. We find that 100 U/ml TNF- alpha/cachectin (TNF), a concentration attainable in the blood of humans with parasitic infestations, stimulates highly purified populations of EOs to damage human umbilical vein endothelial cells (HUVEC), a model of human endothelium. This TNF-dependent EO cytotoxicity is strongly inhibited by heparin and methyprednisolone but unaffected by the platelet-activating factor antagonist BN52012 or scavengers of superoxide anion and H2O2, superoxide dismutase and catalase. However, addition of a physiologically relevant concentration of Br- (100 microM) enhances EO/TNF damage to HUVEC, implicating the possible participation of EO peroxidase (EPO) in the killing mechanism. EOs adherent to FCS-coated plastic wells more than double their production of superoxide anion and the cytotoxic EPO-derived oxidant HOBr when exposed to TNF, showing that TNF activates the respiratory burst of EOs attached to a "physiologic" surface. Unlike PMNs, EOs were not irreversibly activated to kill unopsonized endothelium by previous exposure to TNF, and did not degranulate or upregulate CR3 expression as detected by Mo1 in the presence of 100 U/ml TNF. HUVEC exposed 18 h to TNF were considerably more susceptible to lysis by PMA-activated EOs and reagent H2O2, demonstrating a direct effect of TNF upon endothelium, perhaps through inhibition of antioxidant defenses. These findings suggest that abnormally elevated serum levels of TNF may provoke EOs to damage endothelial cells and thereby play a role in the pathogenesis of tissue damage in hypereosinophilic states.

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman L. C., Hill J. S., Hairfield W. M., Mullarkey M. F. Effects of corticosteroids on eosinophil chemotaxis and adherence. J Clin Invest. 1981 Jan;67(1):28–36. doi: 10.1172/JCI110024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Babior B. M., Kipnes R. S., Curnutte J. T. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest. 1973 Mar;52(3):741–744. doi: 10.1172/JCI107236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  4. Bussolino F., Camussi G., Baglioni C. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. J Biol Chem. 1988 Aug 25;263(24):11856–11861. [PubMed] [Google Scholar]
  5. Butterfield J. H., Maddox D. E., Gleich G. J. The eosinophil leukocyte: maturation and function. Clin Immunol Rev. 1983;2(2):187–306. [PubMed] [Google Scholar]
  6. Collins T., Lapierre L. A., Fiers W., Strominger J. L., Pober J. S. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci U S A. 1986 Jan;83(2):446–450. doi: 10.1073/pnas.83.2.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Creagan E. T., Kovach J. S., Moertel C. G., Frytak S., Kvols L. K. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer. 1988 Dec 15;62(12):2467–2471. doi: 10.1002/1097-0142(19881215)62:12<2467::aid-cncr2820621202>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  8. Fauci A. S., Harley J. B., Roberts W. C., Ferrans V. J., Gralnick H. R., Bjornson B. H. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982 Jul;97(1):78–92. doi: 10.7326/0003-4819-97-1-78. [DOI] [PubMed] [Google Scholar]
  9. Fischer E., Capron M., Prin L., Kusnierz J. P., Kazatchkine M. D. Human eosinophils express CR1 and CR3 complement receptors for cleavage fragments of C3. Cell Immunol. 1986 Feb;97(2):297–306. doi: 10.1016/0008-8749(86)90400-4. [DOI] [PubMed] [Google Scholar]
  10. Gamble J. R., Harlan J. M., Klebanoff S. J., Vadas M. A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8667–8671. doi: 10.1073/pnas.82.24.8667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Heslop H. E., Gottlieb D. J., Bianchi A. C., Meager A., Prentice H. G., Mehta A. B., Hoffbrand A. V., Brenner M. K. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989 Sep;74(4):1374–1380. [PubMed] [Google Scholar]
  12. Kawakami M., Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med. 1981 Sep 1;154(3):631–639. doi: 10.1084/jem.154.3.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kazura J. W., Fanning M. M., Blumer J. L., Mahmoud A. A. Role of cell-generated hydrogen peroxide in granulocyte-mediated killing of schistosomula of Schistosoma mansoni in vitro. J Clin Invest. 1981 Jan;67(1):93–102. doi: 10.1172/JCI110037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kierszenbaum F., Ackerman S. J., Gleich G. J. Destruction of bloodstream forms of Trypanosoma cruzi by eosinophil granule major basic protein. Am J Trop Med Hyg. 1981 Jul;30(4):775–779. doi: 10.4269/ajtmh.1981.30.775. [DOI] [PubMed] [Google Scholar]
  15. Kierszenbaum F., Ackerman S. J., Gleich G. J. Inhibition of antibody-dependent eosinophil-mediated cytotoxicity by heparin. J Immunol. 1982 Jan;128(1):515–517. [PubMed] [Google Scholar]
  16. Klebanoff S. J., Vadas M. A., Harlan J. M., Sparks L. H., Gamble J. R., Agosti J. M., Waltersdorph A. M. Stimulation of neutrophils by tumor necrosis factor. J Immunol. 1986 Jun 1;136(11):4220–4225. [PubMed] [Google Scholar]
  17. Kroegel C., Yukawa T., Dent G., Chanez P., Chung K. F., Barnes P. J. Platelet-activating factor induces eosinophil peroxidase release from purified human eosinophils. Immunology. 1988 Jul;64(3):559–561. [PMC free article] [PubMed] [Google Scholar]
  18. Lamas A. M., Mulroney C. M., Schleimer R. P. Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. J Immunol. 1988 Mar 1;140(5):1500–1505. [PubMed] [Google Scholar]
  19. Larrick J. W., Graham D., Toy K., Lin L. S., Senyk G., Fendly B. M. Recombinant tumor necrosis factor causes activation of human granulocytes. Blood. 1987 Feb;69(2):640–644. [PubMed] [Google Scholar]
  20. Lee T., Lenihan D. J., Malone B., Roddy L. L., Wasserman S. I. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem. 1984 May 10;259(9):5526–5530. [PubMed] [Google Scholar]
  21. Movat H. Z., Burrowes C. E., Cybulsky M. I., Dinarello C. A. Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. Am J Pathol. 1987 Dec;129(3):463–476. [PMC free article] [PubMed] [Google Scholar]
  22. Nathan C. F. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest. 1987 Dec;80(6):1550–1560. doi: 10.1172/JCI113241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Oakley C. M., Olsen G. J. Eosinophilia and heart disease. Br Heart J. 1977 Mar;39(3):233–237. doi: 10.1136/hrt.39.3.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Parrillo J. E., Borer J. S., Henry W. L., Wolff S. M., Fauci A. S. The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med. 1979 Oct;67(4):572–582. doi: 10.1016/0002-9343(79)90227-4. [DOI] [PubMed] [Google Scholar]
  26. Pincus S. H., Butterworth A. E., David J. R., Robbins M., Vadas M. A. Antibody-dependent eosinophil-mediated damage to schistosomula of Schistosoma mansoni: lack of requirement for oxidative metabolism. J Immunol. 1981 May;126(5):1794–1799. [PubMed] [Google Scholar]
  27. Pincus S. H., Dessein A., Lenzi H., Vadas M. A., David J. Eosinophil-mediated killing of schistosomula of Schistosoma mansoni: oxidative requirement for enhancement by eosinophil colony stimulating factor (CSF-alpha) and supernatants with eosinophil cytotoxicity enhancing activity (E-CEA). Cell Immunol. 1984 Sep;87(2):424–433. doi: 10.1016/0008-8749(84)90011-x. [DOI] [PubMed] [Google Scholar]
  28. Roberts R. L., Gallin J. I. Rapid method for isolation of normal human peripheral blood eosinophils on discontinuous Percoll gradients and comparison with neutrophils. Blood. 1985 Feb;65(2):433–440. [PubMed] [Google Scholar]
  29. Rothenberg M. E., Owen W. F., Jr, Silberstein D. S., Soberman R. J., Austen K. F., Stevens R. L. Eosinophils cocultured with endothelial cells have increased survival and functional properties. Science. 1987 Aug 7;237(4815):645–647. doi: 10.1126/science.3110954. [DOI] [PubMed] [Google Scholar]
  30. Sato N., Goto T., Haranaka K., Satomi N., Nariuchi H., Mano-Hirano Y., Sawasaki Y. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst. 1986 Jun;76(6):1113–1121. [PubMed] [Google Scholar]
  31. Scuderi P., Sterling K. E., Lam K. S., Finley P. R., Ryan K. J., Ray C. G., Petersen E., Slymen D. J., Salmon S. E. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet. 1986 Dec 13;2(8520):1364–1365. doi: 10.1016/s0140-6736(86)92007-6. [DOI] [PubMed] [Google Scholar]
  32. Shalaby M. R., Palladino M. A., Jr, Hirabayashi S. E., Eessalu T. E., Lewis G. D., Shepard H. M., Aggarwal B. B. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J Leukoc Biol. 1987 Mar;41(3):196–204. doi: 10.1002/jlb.41.3.196. [DOI] [PubMed] [Google Scholar]
  33. Shau H. Characteristics and mechanism of neutrophil-mediated cytostasis induced by tumor necrosis factor. J Immunol. 1988 Jul 1;141(1):234–240. [PubMed] [Google Scholar]
  34. Silberstein D. S., David J. R. Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci U S A. 1986 Feb;83(4):1055–1059. doi: 10.1073/pnas.83.4.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Slungaard A., Vercellotti G., Zanjani E., Ascensao J., Jacob H. S. Tumor-induced eosinophilia and endocardial fibrosis: evidence for ectopic eosinophilopoietin production and toxic O2 metabolite-mediated endothelial damage. Trans Assoc Am Physicians. 1982;95:8–11. [PubMed] [Google Scholar]
  36. Smedly L. A., Tonnesen M. G., Sandhaus R. A., Haslett C., Guthrie L. A., Johnston R. B., Jr, Henson P. M., Worthen G. S. Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest. 1986 Apr;77(4):1233–1243. doi: 10.1172/JCI112426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Spry C. J., Tai P. C. Studies on blood eosinophils. II. Patients with Löffler's cardiomyopathy. Clin Exp Immunol. 1976 Jun;24(3):423–434. [PMC free article] [PubMed] [Google Scholar]
  38. Tai P. C., Ackerman S. J., Spry C. J., Dunnette S., Olsen E. G., Gleich G. J. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987 Mar 21;1(8534):643–647. doi: 10.1016/s0140-6736(87)90412-0. [DOI] [PubMed] [Google Scholar]
  39. Tauber A. I., Goetzl E. J., Babior B. M. Unique characteristics of superoxide production by human eosinophils in eosinophilic states. Inflammation. 1979 Jul;3(3):261–272. doi: 10.1007/BF00914183. [DOI] [PubMed] [Google Scholar]
  40. Todd R. F., 3rd, Arnaout M. A., Rosin R. E., Crowley C. A., Peters W. A., Babior B. M. Subcellular localization of the large subunit of Mo1 (Mo1 alpha; formerly gp 110), a surface glycoprotein associated with neutrophil adhesion. J Clin Invest. 1984 Oct;74(4):1280–1290. doi: 10.1172/JCI111538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  42. Varani J., Bendelow M. J., Sealey D. E., Kunkel S. L., Gannon D. E., Ryan U. S., Ward P. A. Tumor necrosis factor enhances susceptibility of vascular endothelial cells to neutrophil-mediated killing. Lab Invest. 1988 Aug;59(2):292–295. [PubMed] [Google Scholar]
  43. Veith M. C., Butterworth A. E. Enhancement of human eosinophil-mediated killing of Schistosoma mansoni larvae by mononuclear cell products in vitro. J Exp Med. 1983 Jun 1;157(6):1828–1843. doi: 10.1084/jem.157.6.1828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Vercellotti G. M., Wickham N. W., Gustafson K. S., Yin H. Q., Hebert M., Jacob H. S. Thrombin-treated endothelium primes neutrophil functions: inhibition by platelet-activating factor receptor antagonists. J Leukoc Biol. 1989 Jun;45(6):483–490. doi: 10.1002/jlb.45.6.483. [DOI] [PubMed] [Google Scholar]
  45. Vissers M. C., Day W. A., Winterbourn C. C. Neutrophils adherent to a nonphagocytosable surface (glomerular basement membrane) produce oxidants only at the site of attachment. Blood. 1985 Jul;66(1):161–166. [PubMed] [Google Scholar]
  46. Wassom D. L., Loegering D. A., Solley G. O., Moore S. B., Schooley R. T., Fauci A. S., Gleich G. J. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest. 1981 Mar;67(3):651–661. doi: 10.1172/JCI110080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Weiss S. J., Test S. T., Eckmann C. M., Roos D., Regiani S. Brominating oxidants generated by human eosinophils. Science. 1986 Oct 10;234(4773):200–203. doi: 10.1126/science.3018933. [DOI] [PubMed] [Google Scholar]
  48. Weiss S. J., Young J., LoBuglio A. F., Slivka A., Nimeh N. F. Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest. 1981 Sep;68(3):714–721. doi: 10.1172/JCI110307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Winqvist I., Olofsson T., Olsson I. Mechanisms for eosinophil degranulation; release of the eosinophil cationic protein. Immunology. 1984 Jan;51(1):1–8. [PMC free article] [PubMed] [Google Scholar]
  50. Yazdanbakhsh M., Eckmann C. M., Koenderman L., Verhoeven A. J., Roos D. Eosinophils do respond to fMLP. Blood. 1987 Aug;70(2):379–383. [PubMed] [Google Scholar]
  51. Zimmerman R. J., Chan A., Leadon S. A. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res. 1989 Apr 1;49(7):1644–1648. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES